Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
PRISM BioLab Slips on Profit-Taking Despite Joint Presentation with Eisai on E7386 Preclinical Data◇
Shares of PRISM BioLab <206A> experienced volatile trading. After the market close on the 6th, the company announced that Eisai <4523> will present preclinical study results regarding the combination therapy of "E7386"?a compound co-developed by the two companies?and the anticancer drug "Lenvima." The study indicated that the combination of E7386 and Lenvima demonstrated stronger anti-angiogenic effects on tumor microvessels and higher antitumor activity compared to Lenvima monotherapy. While PRISM BioLab's stock opened higher on this positive news, it subsequently gave up its gains as profit-taking emerged. Eisai is currently conducting clinical trials for the E7386 and Lenvima combination therapy targeting advanced solid tumors, including endometrial cancer.
Related Articles
Shares of GA technologies rise on announcement of SPC Securities acquisition
Kimura Chemical Plants rebounds for the first time in nine days on joining bioethanol consortium
Union Tool shares fall sharply on dilution concerns following its decision to sell treasury stock.
Intermestic Shares Surge as March Same-Store Sales Jump 12.7% YoY, Fueled by 'Chiikawa' Co-Branded Collection
SoftBank Group shares rise for a third consecutive session, but upside is capped despite the unwinding of margin longs.
ICHIBANYA Snaps 3-Day Winning Streak After Lowering Operating Profit Target in Medium-Term Management Plan
AEON Fantasy Stages a Sharp Rebound from Recent Lows, Gaining for a Sixth Straight Session on Major Earnings Upgrade
ALPHA Opens with a Flood of Buy Orders, Buoyed by Upgraded Sept-Feb Forecast and Dividend Hike
NEXTAGE Shares Surge as Q1 Operating Profit Jumps 180%
Hito to Hito Holdings <549A> Debuts on TSE Standard Market at \422, 1.9% Below Offering Price